[article] 
inAutism Research > 14-6 (June 2021) . - p.1271-1283

Titre :	Evidence-based use of scalable biomarkers to increase diagnostic efficiency and decrease the lifetime costs of autism
Type de document :	Texte imprimé et/ou numérique
Auteurs :	T. W. FRAZIER, Auteur ; D. L. COURY, Auteur ; K. SOHL, Auteur ; Kayla E. WAGNER, Auteur ; R. UHLIG, Auteur ; S. D. HICKS, Auteur ; F. A. MIDDLETON, Auteur
Article en page(s) :	p.1271-1283
Langues :	Anglais (eng)
Mots-clés :	Autism Spectrum Disorder/diagnosis  Autistic Disorder  Biomarkers  Child  Early Diagnosis  Humans  Mass Screening  United States  autism spectrum disorder  biomarkers  cost analysis  early diagnosis  evidence-based assessment  developer of the eye tracking test that was used in the EBM analysis. Thomas W.  Frazier has received federal funding or research support from, acted as a consultant  to, received travel support from, and/or received a speaker's honorarium from  Quadrant Biosciences, Impel NeuroPharma, F. Hoffmann?La Roche AG Pharmaceuticals,  the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest  Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol?Myers  Squibb, Roche Pharma, National Institutes of Health, and the Brain and Behavior  Research Foundation and has an investor stake in AutismEYES LLC. Steven D. Hicks and  Frank A. Middleton are co?developers of the saliva RNA based autism test that is  used in the EBM analysis, and members of the Clinical and Scientific Advisory Boards  of Quadrant Biosciences. Kristin Sohl is director of ECHO Autism and both Kristin  Sohl and Daniel L. Coury are a member of the Clinical Advisory Board of Quadrant  Biosciences. Daniel L. Coury has received federal funding or research support from  National Institutes of Health, GW Biosciences, Neurim, Stemina Biosciences, and  Stalicla SA  and acted as a consultant to BioRosa, Cognoa, GW Biosciences, and  Stalicla SA. Kayla E. Wagner and Richard Uhlig are employees of Quadrant  Biosciences. Quadrant Biosciences holds patent rights and exclusive sales rights for  the Clarifi ASD saliva test.
Index. décimale :	PER Périodiques
Résumé :	Challenges associated with the current screening and diagnostic process for autism spectrum disorder (ASD) in the US cause a significant delay in the initiation of evidence-based interventions at an early age when treatments are most effective. The present study shows how implementing a second-order diagnostic measure to high risk cases initially flagged positive from screening tools can further inform clinical judgment and substantially improve early identification. We use two example measures for the purposes of this demonstration; a saliva test and eye-tracking technology, both scalable and easy-to-implement biomarkers recently introduced in ASD research. Results of the current cost-savings analysis indicate that lifetime societal cost savings in special education, medical and residential care are estimated to be nearly $580,000 per ASD child, with annual cost savings in education exceeding $13.3 billion, and annual cost savings in medical and residential care exceeding $23.8 billion (of these, nearly $11.2 billion are attributable to Medicaid). These savings total more than $37 billion/year in societal savings in the US. Initiating appropriate interventions faster and reducing the number of unnecessary diagnostic evaluations can decrease the lifetime costs of ASD to society. We demonstrate the value of implementing a scalable highly accurate diagnostic in terms of cost savings to the US. LAY SUMMARY: This paper demonstrates how biomarkers with high accuracy for detecting autism spectrum disorder (ASD) could be used to increase the efficiency of early diagnosis. Results also show that, if more children with ASD are identified early and referred for early intervention services, the system would realize substantial costs savings across the lifespan.
En ligne :	http://dx.doi.org/10.1002/aur.2498
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449

[article] Evidence-based use of scalable biomarkers to increase diagnostic efficiency and decrease the lifetime costs of autism [Texte imprimé et/ou numérique] / T. W. FRAZIER, Auteur ; D. L. COURY, Auteur ; K. SOHL, Auteur ; Kayla E. WAGNER, Auteur ; R. UHLIG, Auteur ; S. D. HICKS, Auteur ; F. A. MIDDLETON, Auteur . - p.1271-1283.
Langues : Anglais (eng)
in Autism Research > 14-6 (June 2021) . - p.1271-1283

Mots-clés :	Autism Spectrum Disorder/diagnosis  Autistic Disorder  Biomarkers  Child  Early Diagnosis  Humans  Mass Screening  United States  autism spectrum disorder  biomarkers  cost analysis  early diagnosis  evidence-based assessment  developer of the eye tracking test that was used in the EBM analysis. Thomas W.  Frazier has received federal funding or research support from, acted as a consultant  to, received travel support from, and/or received a speaker's honorarium from  Quadrant Biosciences, Impel NeuroPharma, F. Hoffmann?La Roche AG Pharmaceuticals,  the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest  Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol?Myers  Squibb, Roche Pharma, National Institutes of Health, and the Brain and Behavior  Research Foundation and has an investor stake in AutismEYES LLC. Steven D. Hicks and  Frank A. Middleton are co?developers of the saliva RNA based autism test that is  used in the EBM analysis, and members of the Clinical and Scientific Advisory Boards  of Quadrant Biosciences. Kristin Sohl is director of ECHO Autism and both Kristin  Sohl and Daniel L. Coury are a member of the Clinical Advisory Board of Quadrant  Biosciences. Daniel L. Coury has received federal funding or research support from  National Institutes of Health, GW Biosciences, Neurim, Stemina Biosciences, and  Stalicla SA  and acted as a consultant to BioRosa, Cognoa, GW Biosciences, and  Stalicla SA. Kayla E. Wagner and Richard Uhlig are employees of Quadrant  Biosciences. Quadrant Biosciences holds patent rights and exclusive sales rights for  the Clarifi ASD saliva test.
Index. décimale :	PER Périodiques
Résumé :	Challenges associated with the current screening and diagnostic process for autism spectrum disorder (ASD) in the US cause a significant delay in the initiation of evidence-based interventions at an early age when treatments are most effective. The present study shows how implementing a second-order diagnostic measure to high risk cases initially flagged positive from screening tools can further inform clinical judgment and substantially improve early identification. We use two example measures for the purposes of this demonstration; a saliva test and eye-tracking technology, both scalable and easy-to-implement biomarkers recently introduced in ASD research. Results of the current cost-savings analysis indicate that lifetime societal cost savings in special education, medical and residential care are estimated to be nearly $580,000 per ASD child, with annual cost savings in education exceeding $13.3 billion, and annual cost savings in medical and residential care exceeding $23.8 billion (of these, nearly $11.2 billion are attributable to Medicaid). These savings total more than $37 billion/year in societal savings in the US. Initiating appropriate interventions faster and reducing the number of unnecessary diagnostic evaluations can decrease the lifetime costs of ASD to society. We demonstrate the value of implementing a scalable highly accurate diagnostic in terms of cost savings to the US. LAY SUMMARY: This paper demonstrates how biomarkers with high accuracy for detecting autism spectrum disorder (ASD) could be used to increase the efficiency of early diagnosis. Results also show that, if more children with ASD are identified early and referred for early intervention services, the system would realize substantial costs savings across the lifespan.
En ligne :	http://dx.doi.org/10.1002/aur.2498
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449